Adsett Roger 4

What Happened
Roger Adsett, a director of Definium Therapeutics, was granted a derivative award on January 29, 2026 covering 50,000 shares. The reported acquisition price is $0.00 (a zero-dollar grant entry typical for option awards on Form 4); no cash was paid at grant. This is an award of an option-like instrument, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-29 (reported filing date: 2026-01-29) — filing appears timely.
• Transaction type: Grant / Award (derivative instrument) of 50,000 shares; reported price $0.00.
• Vesting/exercise terms: Per footnote, the shares underlying the option vest and become exercisable over three years — 1/3 on the first anniversary of the grant, with the remaining 2/3 vesting in 24 equal monthly installments thereafter, subject to continuous service.
• Shares owned after transaction: Not specified in the provided excerpt of the filing (check full Form 4 for "Amount Beneficially Owned" if needed).
• No indication of a sale, cashless exercise, tax withholding, 10b5-1 plan, or late filing in the disclosed entry.

Context
This is a standard equity compensation grant to a director. It does not involve an immediate purchase or sale of stock and does not on its own signal insider buying or selling — value will depend on future vesting, exercisability, and any eventual exercise price. Retail investors tracking insider activity should note the vesting schedule and monitor future filings for exercises or open-market transactions.